Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06712030 | NOT YET RECRUITING | Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction
Sponsor:

Puerta de Hierro University Hospital

Information provided by (Responsible Party):

Esther Gonzalez Lopez

Brief Summary:

Prospective, randomized, multicenter, open-label clinical trial to evaluate the safety and efficacy of Sacubitril/Valsartan (Sac/Vals) compared to no initiation of the drug in patients with transthyretin cardiac amyloidosis (ATTR) and heart failure with reduced ejection fraction (LVEF ≤40%). The primary objective is to determine the impact of Sac/Vals treatment on systolic function by assessing the change in LVEF on echocardiogram at 12-month follow-up.

Condition or disease

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Intervention/treatment

Sacubitril / Valsartan

Phase

PHASE3

Detailed Description:

Transthyretin cardiac amyloidosis (ATTR) has emerged as a prevalent and underdiagnosed cause of heart failure (HF), affecting patients both with preserved left ventricular ejection fraction (LVEF) and with systolic dysfunction. It remains unclear whether this population benefits from standard treatments for HF with reduced LVEF or whether treatment with renin-angiotensin system inhibitors and neprilysin might even be harmful in ATTR. The investigators plan to conduct a prospective, randomized, multicenter, open-label clinical trial to evaluate the safety and efficacy of Sacubitril/Valsartan (Sac/Vals), as recommended in current HF guidelines, versus no treatment in patients with ATTR and heart failure with reduced ejection fraction (HFrEF), including those with LVEF ≤40%. Approximately 114 patients from four Spanish centers will be randomized 1:1 to receive Sac/Vals treatment (up to the maximum tolerated dose) or to not initiate the drug, with stratification by center and tafamidis treatment. It has been included a run-in period with a low dose of Sac/Vals to assess tolerance prior to randomization. Patients will have scheduled follow-up visits at 3, 6, and 12 months, during which clinical, functional, analytical, electrocardiographic, and echocardiographic variables will be evaluated. The primary objective is to determine the impact of Sac/Vals treatment on systolic function in patients with ATTR and HFrEF by assessing the change in LVEF on echocardiogram at 12 months. Improvement in LVEF will be defined as an increase of ≥5% from the baseline echocardiogram to the 12-month follow-up.

Study Type : INTERVENTIONAL
Estimated Enrollment : 114 participants
Masking : SINGLE
Masking Description : The analysis of the echocardiogram will be performed by evaluators blinded to the treatment and the timing of the imaging.
Primary Purpose : TREATMENT
Official Title : Effect of Pharmacological Treatment with Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction (SAVA-TTR)
Actual Study Start Date : 2025-01
Estimated Primary Completion Date : 2027-04
Estimated Study Completion Date : 2027-06

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Patients ≥ 18 years of age of both sexes.
  • * Patients diagnosed with ATTR cardiac amyloidosis as indicated in guidelines, both in its hereditary form (ATTRv) or wild-type form (ATTRwt).
  • * Patients initially evaluated or under follow-up in Cardiomyopathy/Heart Failure/Amyloidosis Units at participating centers.
  • * Heart failure and reduced ejection fraction: LVEF ≤40%, in functional class I, II, or III according to the New York Heart Association (NYHA).
Exclusion Criteria
  • * NYHA Functional Class IV.
  • * Stage 4 and 5 chronic kidney disease (creatinine clearance by CKD-EPI \<30 mL/min/1.73m²).
  • * Hyperkalemia (blood potassium levels \> 5.4 mmol/L).
  • * Hypotension defined as systolic blood pressure (SBP) \<100 mmHg on two consecutive measurements.
  • * Treatment with ACE inhibitors, ARBs, or sacubitril/valsartan at the time of enrollment.
  • * History of angioedema or hypersensitivity to ACE inhibitors or ARBs.
  • * Treatment with TTR gene silencers or diflunisal.
  • * Participation in another clinical trial.
  • * Pregnancy, breastfeeding, or fertile women unwilling to use adequate contraception throughout the study duration.
  • * Any condition that, in the investigator's opinion, compromises participation in the study.
Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

Location Details

NCT06712030

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

Spain, Madrid

Puerta de Hierro University Hospital

Majadahonda, Madrid, Spain, 28222